Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study

被引:45
|
作者
Mitja, Oriol [1 ,2 ,3 ]
Godornes, Charmie [4 ]
Houinei, Wendy [6 ]
Kapa, August [3 ]
Paru, Raymond [3 ]
Abel, Haina [3 ]
Gonzalez-Beiras, Camila [1 ,7 ]
Bieb, Sibauk V. [6 ]
Wangi, James [8 ]
Barry, Alyssa E. [9 ,10 ]
Sanz, Sergi [1 ,13 ]
Bassat, Quique [1 ,11 ,12 ,14 ]
Lukehart, Sheila A. [4 ,5 ]
机构
[1] Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth, Barcelona, Spain
[2] Univ Papua New Guinea, Sch Med & Hlth Sci, Div Publ Hlth, Port Moresby, Papua N Guinea
[3] Int SOS Newcrest Min, Lihir Med Ctr, Lihir Isl, Papua N Guinea
[4] Univ Washington, Dept Med, Seattle, WA USA
[5] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
[6] Natl Dept Hlth, Dis Control Branch, Port Moresby, Papua N Guinea
[7] Lisbon Inst Hyg & Trop Med, Lisbon, Portugal
[8] WHO, Off World Hlth Org WHO Representat Papua New Guin, Port Moresby, Papua N Guinea
[9] Walter & Eliza Hall Inst Med Res, Populat Hlth & Immun Div, Parkville, Vic, Australia
[10] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia
[11] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain
[12] Ctr Invest Saude Manhica, Maputo, Mozambique
[13] Univ Barcelona, Dept Publ Hlth, Biostat Unit, Fac Med, Barcelona, Spain
[14] Hosp St Joan de Deu, Dept Paediat, Paediat Infect Dis Unit, Barcelona, Spain
来源
LANCET | 2018年 / 391卷 / 10130期
基金
美国国家卫生研究院;
关键词
PAPUA-NEW-GUINEA; TREPONEMA-PALLIDUM; MACROLIDE RESISTANCE; HAEMOPHILUS-DUCREYI; DOSE AZITHROMYCIN; POINT MUTATION; UNITED-STATES; SKIN ULCERS; PREVALENCE; CHILDREN;
D O I
10.1016/S0140-6736(18)30204-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Yaws is a substantial cause of chronic disfiguring ulcers in children in at least 14 countries in the tropics. WHO's newly adopted strategy for yaws eradication uses a single round of mass azithromycin treatment followed by targeted treatment programmes, and data from pilot studies have shown a short-term significant reduction of yaws. We assessed the long-term efficacy of the WHO strategy for yaws eradication. Methods Between April 15, 2013, and Oct 24, 2016, we did a longitudinal study on a Papua New Guinea island (Lihir; 16 092 population) in which yaws was endemic. In the initial study, the participants were followed for 12 months; in this extended follow-up study, clinical, serological, and PCR surveys were continued every 6 months for 42 months. We used genotyping and travel history to identify importation events. Active yaws confirmed by PCR specific for Treponema pallidum was the primary outcome indicator. The study is registered with ClinicalTrials.gov, number NCT01955252. Findings Mass azithromycin treatment (coverage rate of 84%) followed by targeted treatment programmes reduced the prevalence of active yaws from 1.8% to a minimum of 0.1% at 18 months (difference from baseline -1.7%, 95% CI, -1.9 to -1.4; p<0.0001), but the infection began to re-emerge after 24 months with a significant increase to 0.4% at 42 months (difference from 18 months 0.3%, 95% CI 0.1 to 0.4; p<0.0001). At each timepoint after baseline, more than 70% of the total community burden of yaws was found in individuals who had not had the mass treatment or as new infections in non-travelling residents. At months 36 and 42, five cases of active yaws, all from the same village, showed clinical failure following azithromycin treatment, with PCR-detected mutations in the 23S ribosomal RNA genes conferring resistance to azithromycin. A sustained decrease in the prevalence of high-titre latent yaws from 13.7% to <1.5% in asymptomatic children aged 1-5 years old and of genetic diversity of yaws strains from 0.139 to less than 0.046 between months 24 and 42 indicated a reduction in transmission of infection. Interpretation The implementation of the WHO strategy did not, in the long-term, achieve elimination in a high-endemic community mainly due to the individuals who were absent at the time of mass treatment in whom yaws reactivated; repeated mass treatment might be necessary to eliminate yaws. To our knowledge, this is the first report of the emergence of azithromycin-resistant T p pertenue and spread within one village. Communities' surveillance should be strengthened to detect any possible treatment failure and biological markers of resistance.
引用
下载
收藏
页码:1599 / 1607
页数:9
相关论文
共 50 条
  • [1] Yaws re-emergence and bacterial drug resistance selection after mass administration of azithromycin: a genomic epidemiology investigation
    Beale, Mathew A.
    Noguera-Julian, Marc
    Godornes, Charmie
    Casadella, Maria
    Gonzalez-Beiras, Camila
    Parera, Monona
    Jnr, August Kapa
    Houinei, Wendy
    Wangi, James
    Corbacho-Monne, Marc
    Paredes, Roger
    Gonzalez-Candelas, Fernando
    Marks, Michael
    Lukehart, Sheila A.
    Thomson, Nicholas R.
    Mitja, Oriol
    LANCET MICROBE, 2020, 1 (06): : E263 - E271
  • [2] Mass Treatment with Single-Dose Azithromycin for Yaws
    Tepper, Martin
    Whitehead, Jeff
    Maher, Maurica
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (11): : 1093 - 1094
  • [3] Mass Treatment with Single-Dose Azithromycin for Yaws
    Mitja, Oriol
    Houinei, Wendy
    Moses, Penias
    Kapa, August
    Paru, Raymond
    Hays, Russell
    Lukehart, Sheila
    Godornes, Charmie
    Bieb, Sibauk Vivaldo
    Grice, Tim
    Siba, Peter
    Mabey, David
    Sanz, Sergi
    Alonso, Pedro L.
    Asiedu, Kingsley
    Bassat, Quique
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 703 - 710
  • [4] Mass Treatment with Single-Dose Azithromycin for Yaws Reply
    Mitja, Oriol
    Lukehart, Sheila
    Bassat, Quique
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (11): : 1094 - 1094
  • [5] Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community:: a longitudinal study
    Burton, MJ
    Holland, MJ
    Makalo, P
    Aryee, EAN
    Alexander, NDE
    Sillah, A
    Faal, H
    West, SK
    Foster, A
    Johnson, GJ
    Mabey, DCW
    Bailey, RL
    LANCET, 2005, 365 (9467): : 1321 - 1328
  • [6] Re-emergence of Babesia conradae and effective treatment of infected dogs with atovaquone and azithromycin
    Di Cicco, Michael F.
    Downey, Megan E.
    Beeler, Emily
    Marr, Henry
    Cyrog, Peter
    Kidd, Linda
    Diniz, Pedro Paulo V. P.
    Cohn, Leah A.
    Birkenheuer, Adam J.
    VETERINARY PARASITOLOGY, 2012, 187 (1-2) : 23 - 27
  • [7] Re-emergence of tuberculosis: strategies and treatment
    Kremer, L
    Besra, GS
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (02) : 153 - 157
  • [8] Towards eradication of yaws disease by 2020 using a single dose of azithromycin in mass treatment
    Revankar, C. R.
    Asiedu, K.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 388 - 388
  • [9] Breast cancer dormancy, re-emergence, and treatment
    Beckwitt, C.
    Wheeler, S. E.
    Clark, A. M.
    Pillai, V. C.
    Young, C. L.
    Stolz, D. B.
    Lauffenburger, D. A.
    Venkataramanan, R.
    Griffith, L. G.
    Wells, A.
    CANCER RESEARCH, 2016, 76
  • [10] Impact of Community Mass Treatment with Azithromycin for Trachoma Elimination on the Prevalence of Yaws
    Marks, Michael
    Vahi, Ventis
    Sokana, Oliver
    Chi, Kai-Hua
    Puiahi, Elliot
    Kilua, Georgina
    Pillay, Allan
    Dalipanda, Tenneth
    Bottomley, Christian
    Solomon, Anthony W.
    Mabey, David C.
    PLOS NEGLECTED TROPICAL DISEASES, 2015, 9 (08):